AF
HOWL icon

Amalgamated Financial’s Werewolf Therapeutics HOWL Stock Holding History

Amalgamated Financial’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$17K Buy
+3,946
New +$27.6K ﹤0.01% 2787

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Amalgamated Financial's HOWL Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Werewolf Therapeutics (HOWL) in Q1 2022: 3,946 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #2787 among its holdings.

49 funds tracked by Wall St. Rank hold HOWL as of Q1 2022.

  • Amalgamated Financial held 3,946 shares of Werewolf Therapeutics worth $17K as of Q1 2022.
  • Werewolf Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Werewolf Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2787 holding.
  • 49 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.